161 related articles for article (PubMed ID: 36436128)
1. Adjuvant endocrine therapy non-initiation and non-persistence in young women with early-stage breast cancer.
Rosenberg SM; Zheng Y; Gelber S; Ruddy KJ; Poorvu P; Sella T; Tamimi RM; Wassermann J; Schapira L; Borges VF; Come S; Peppercorn J; Sepucha KR; Partridge AH
Breast Cancer Res Treat; 2023 Feb; 197(3):547-558. PubMed ID: 36436128
[TBL] [Abstract][Full Text] [Related]
2. Psychosocial factors related to non-persistence with adjuvant endocrine therapy among women with breast cancer: the Breast Cancer Quality of Care Study (BQUAL).
Hershman DL; Kushi LH; Hillyer GC; Coromilas E; Buono D; Lamerato L; Bovbjerg DH; Mandelblatt JS; Tsai WY; Zhong X; Jacobson JS; Wright JD; Neugut AI
Breast Cancer Res Treat; 2016 May; 157(1):133-43. PubMed ID: 27086286
[TBL] [Abstract][Full Text] [Related]
3. Survival benefits associated with being adherent and having longer persistence to adjuvant hormone therapy across up to five years among U.S. Medicare population with breast cancer.
Zheng D; Thomas J
Breast Cancer Res Treat; 2023 Aug; 201(1):89-104. PubMed ID: 37326766
[TBL] [Abstract][Full Text] [Related]
4. Nonadherent behaviors among young women on adjuvant endocrine therapy for breast cancer.
Wassermann J; Gelber SI; Rosenberg SM; Ruddy KJ; Tamimi RM; Schapira L; Borges VF; Come SE; Meyer ME; Partridge AH
Cancer; 2019 Sep; 125(18):3266-3274. PubMed ID: 31120571
[TBL] [Abstract][Full Text] [Related]
5. Endocrine therapy use in the twenty-first century: usage rates and temporal trends illustrate opportunities for improvement for South Carolina Medicaid women.
Bedi JS; Mayo RM; Truong K; Chen L; Dickes L; Sherrill WW; Jones K
Breast Cancer Res Treat; 2018 Oct; 171(3):759-765. PubMed ID: 29971626
[TBL] [Abstract][Full Text] [Related]
6. Factors Associated with Endocrine Therapy Non-Adherence in Breast Cancer Survivors.
Spencer JC; Reeve BB; Troester MA; Wheeler SB
Psychooncology; 2020 Apr; 29(4):647-654. PubMed ID: 32048400
[TBL] [Abstract][Full Text] [Related]
7. Can demographic, clinical and treatment-related factors available at hormonal therapy initiation predict non-persistence in women with stage I-III breast cancer?
Cahir C; Barron TI; Sharp L; Bennett K
Cancer Causes Control; 2017 Mar; 28(3):215-225. PubMed ID: 28210883
[TBL] [Abstract][Full Text] [Related]
8. Racial Differences in Patient-Reported Symptoms and Adherence to Adjuvant Endocrine Therapy Among Women With Early-Stage, Hormone Receptor-Positive Breast Cancer.
Hu X; Walker MS; Stepanski E; Kaplan CM; Martin MY; Vidal GA; Schwartzberg LS; Graetz I
JAMA Netw Open; 2022 Aug; 5(8):e2225485. PubMed ID: 35947386
[TBL] [Abstract][Full Text] [Related]
9. Impact of patient race and geographical factors on initiation and adherence to adjuvant endocrine therapy in medicare breast cancer survivors.
Camacho FT; Tan X; Alcalá HE; Shah S; Anderson RT; Balkrishnan R
Medicine (Baltimore); 2017 Jun; 96(24):e7147. PubMed ID: 28614244
[TBL] [Abstract][Full Text] [Related]
10. Initiation and adherence to adjuvant endocrine therapy among urban, insured American Indian/Alaska Native breast cancer survivors.
Emerson MA; Achacoso NS; Benefield HC; Troester MA; Habel LA
Cancer; 2021 Jun; 127(11):1847-1856. PubMed ID: 33620753
[TBL] [Abstract][Full Text] [Related]
11. A nested case-control study of adjuvant hormonal therapy persistence and compliance, and early breast cancer recurrence in women with stage I-III breast cancer.
Barron TI; Cahir C; Sharp L; Bennett K
Br J Cancer; 2013 Sep; 109(6):1513-21. PubMed ID: 24002590
[TBL] [Abstract][Full Text] [Related]
12. Perceptions, Attributions, and Emotions Toward Endocrine Therapy in Young Women with Breast Cancer.
Walker HE; Rosenberg SM; Stanton AL; Petrie KJ; Partridge AH
J Adolesc Young Adult Oncol; 2016 Mar; 5(1):16-23. PubMed ID: 26812461
[TBL] [Abstract][Full Text] [Related]
13. Personal and clinical social support and adherence to adjuvant endocrine therapy among hormone receptor-positive breast cancer patients in an integrated health care system.
Kroenke CH; Hershman DL; Gomez SL; Adams SR; Eldridge EH; Kwan ML; Ergas IJ; Kubo A; Kushi LH
Breast Cancer Res Treat; 2018 Aug; 170(3):623-631. PubMed ID: 29671113
[TBL] [Abstract][Full Text] [Related]
14. Adherence to adjuvant hormonal therapy among breast cancer survivors in clinical practice: a systematic review.
Murphy CC; Bartholomew LK; Carpentier MY; Bluethmann SM; Vernon SW
Breast Cancer Res Treat; 2012 Jul; 134(2):459-78. PubMed ID: 22689091
[TBL] [Abstract][Full Text] [Related]
15. Association of Adjuvant Hormone Therapy Timing With Overall Survival Among Patients With Hormone Receptor-Positive Human Epidermal Growth Factor Receptor-2-Negative Early Breast Cancer Without Chemotherapy.
Fu F; Yu L; Zeng B; Chen M; Guo W; Chen L; Lin Y; Hou J; Li J; Li Y; Li S; Chen X; Zhang W; Jin X; Cai W; Zhang K; Chen H; Qiu Y; Nie Q; Wang C; Jacobs L
JAMA Netw Open; 2022 Feb; 5(2):e2145934. PubMed ID: 35166783
[TBL] [Abstract][Full Text] [Related]
16. Patient-reported factors associated with adherence to adjuvant endocrine therapy after breast cancer: an integrative review.
Lambert LK; Balneaves LG; Howard AF; Gotay CC
Breast Cancer Res Treat; 2018 Feb; 167(3):615-633. PubMed ID: 29110151
[TBL] [Abstract][Full Text] [Related]
17. Racial/ethnic differences in initiation of adjuvant hormonal therapy among women with hormone receptor-positive breast cancer.
Livaudais JC; Hershman DL; Habel L; Kushi L; Gomez SL; Li CI; Neugut AI; Fehrenbacher L; Thompson B; Coronado GD
Breast Cancer Res Treat; 2012 Jan; 131(2):607-17. PubMed ID: 21922245
[TBL] [Abstract][Full Text] [Related]
18. Persistence to extended adjuvant endocrine therapy following Breast Cancer Index (BCI) testing in women with early-stage hormone receptor-positive (HR +) breast cancer.
Foldi J; Tsagianni A; Salganik M; Schnabel CA; Brufsky A; van Londen GJ; Pusztai L; Sanft T
BMC Cancer; 2023 Jun; 23(1):606. PubMed ID: 37391697
[TBL] [Abstract][Full Text] [Related]
19. Breast cancer patients' experiences of adherence and persistence to oral endocrine therapy: A qualitative evidence synthesis.
Clancy C; Lynch J; OConnor P; Dowling M
Eur J Oncol Nurs; 2020 Feb; 44():101706. PubMed ID: 32007696
[TBL] [Abstract][Full Text] [Related]
20. Clinical factors associated with patterns of endocrine therapy adherence in premenopausal breast cancer patients.
Woolpert KM; Schmidt JA; Ahern TP; Hjorth CF; Farkas DK; Ejlertsen B; Collin LJ; Lash TL; Cronin-Fenton DP
Breast Cancer Res; 2024 Apr; 26(1):59. PubMed ID: 38589932
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
